548 related articles for article (PubMed ID: 23729309)
1. Current and future treatments for Behçet's uveitis: road to remission.
Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Dick AD; Adán A
Int Ophthalmol; 2014 Apr; 34(2):365-81. PubMed ID: 23729309
[TBL] [Abstract][Full Text] [Related]
2. Behçet's disease: ocular effects and treatment.
Deuter CM; Kötter I; Wallace GR; Murray PI; Stübiger N; Zierhut M
Prog Retin Eye Res; 2008 Jan; 27(1):111-36. PubMed ID: 18035584
[TBL] [Abstract][Full Text] [Related]
3. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.
Benitah NR; Sobrin L; Papaliodis GN
Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178
[TBL] [Abstract][Full Text] [Related]
4. [Eye and Behçet's disease].
Ksiaa I; Abroug N; Kechida M; Zina S; Jelliti B; Khochtali S; Attia S; Khairallah M
J Fr Ophtalmol; 2019 Jun; 42(6):626-641. PubMed ID: 31164292
[TBL] [Abstract][Full Text] [Related]
5. Eye and Behçet's disease.
Ksiaa I; Abroug N; Kechida M; Zina S; Jelliti B; Khochtali S; Attia S; Khairallah M
J Fr Ophtalmol; 2019 Apr; 42(4):e133-e146. PubMed ID: 30850197
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.
Sugita S; Kawazoe Y; Imai A; Yamada Y; Horie S; Mochizuki M
Arthritis Res Ther; 2012 May; 14(3):R99. PubMed ID: 22546542
[TBL] [Abstract][Full Text] [Related]
7. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
Park JY; Chung YR; Lee K; Song JH; Lee ES
Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144
[TBL] [Abstract][Full Text] [Related]
8. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
9. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
Atienza-Mateo B; Calvo-Río V; Beltrán E; Martínez-Costa L; Valls-Pascual E; Hernández-Garfella M; Atanes A; Cordero-Coma M; Miquel Nolla J; Carrasco-Cubero C; Loricera J; González-Vela MC; Vegas-Revenga N; Fernández-Díaz C; Demetrio-Pablo R; Domínguez-Casas LC; Luis Martín-Varillas J; Palmou-Fontana N; Hernández JL; González-Gay MÁ; Blanco R
Rheumatology (Oxford); 2018 May; 57(5):856-864. PubMed ID: 29471416
[TBL] [Abstract][Full Text] [Related]
10. Behçet's Uveitis: Current Diagnostic and Therapeutic Approach.
Çakar Özdal P
Turk J Ophthalmol; 2020 Jun; 50(3):169-182. PubMed ID: 32631005
[TBL] [Abstract][Full Text] [Related]
11. [Ocular manifestations in Behçet's disease].
Desbois AC; Terrada C; Cacoub P; Bodaghi B; Saadoun D
Rev Med Interne; 2018 Sep; 39(9):738-745. PubMed ID: 29625716
[TBL] [Abstract][Full Text] [Related]
12. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Gentileschi S; Bacherini D; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):191-197. PubMed ID: 27981463
[TBL] [Abstract][Full Text] [Related]
13. An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.
McNally TW; Damato EM; Murray PI; Denniston AK; Barry RJ
Orphanet J Rare Dis; 2017 Jul; 12(1):130. PubMed ID: 28716038
[TBL] [Abstract][Full Text] [Related]
14. Treatment with Biologic Drugs in Pediatric Behçet's Disease: A Comprehensive Analysis of the Published Data.
Batu ED; Sener S; Cam V; Aktay Ayaz N; Ozen S
BioDrugs; 2023 Nov; 37(6):813-828. PubMed ID: 37382804
[TBL] [Abstract][Full Text] [Related]
15. Comparing biologic options for the management of Behcet's disease-related uveitis.
Vitale A; Caggiano V; Berlengiero V; Perfetti MO; Sota J; Tosi GM; Frediani B; Cantarini L; Fabiani C
Expert Rev Clin Immunol; 2023 Mar; 19(3):315-328. PubMed ID: 36715297
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
Zlatanović G; Jovanović S; Veselinović D; Zivković M
Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
[TBL] [Abstract][Full Text] [Related]
17. Immunopathogenesis of ocular Behçet's disease.
Park UC; Kim TW; Yu HG
J Immunol Res; 2014; 2014():653539. PubMed ID: 25061613
[TBL] [Abstract][Full Text] [Related]
18. Behçet's disease: New insights into pathophysiology, clinical features and treatment options.
Greco A; De Virgilio A; Ralli M; Ciofalo A; Mancini P; Attanasio G; de Vincentiis M; Lambiase A
Autoimmun Rev; 2018 Jun; 17(6):567-575. PubMed ID: 29631062
[TBL] [Abstract][Full Text] [Related]
19. Early administration of adalimumab for paediatric uveitis due to Behçet's disease.
Hiyama T; Harada Y; Doi T; Kiuchi Y
Pediatr Rheumatol Online J; 2019 Jun; 17(1):29. PubMed ID: 31182107
[TBL] [Abstract][Full Text] [Related]
20. [Biologics in uveitis].
Feurer E; Bielefeld P; Saadoun D; Sève P
Rev Med Interne; 2015 Feb; 36(2):107-16. PubMed ID: 25239400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
